Investors Sue Keryx Over $1.3B Merger With Akebia
Keryx Biopharmaceuticals Inc. misled investors about the company's financial future in documents related to its $1.3 billion acquisition by Akebia Therapeutics Inc., shareholders alleged in a proposed securities class action filed...To view the full article, register now.
Already a subscriber? Click here to view full article